FDA Authorizes Aletta: First-of-Its-Kind Robotic Blood Draw Device
<>
The U.S. Food and Drug Administration (FDA) authorized the Aletta on August 19, 2026, marking the first time a standalone robotic system has been cleared to autonomously perform blood draws from a patient’s arm without hands-on operator intervention. Developed by Vitestro, the device targets the growing U.S. phlebotomist shortage by allowing a single trained supervisor to oversee up to three units simultaneously in outpatient settings.
The Tech TL;DR:
- Autonomous Workflow: The Aletta utilizes near-infrared light and Doppler ultrasound to map vasculature, autonomously performing tourniquet application, skin disinfection, needle insertion, and tube exchange.
- Operational Efficiency: Designed for outpatient scaling, the system allows one phlebotomist to supervise three devices, directly addressing clinical staffing bottlenecks.
- Safety Architecture: Integrated fail-safes include real-time movement detection that triggers automatic needle retraction and persistent disinfectant application during the scanning phase.
Architectural Logic and Sensor Fusion
According to FDA documentation, the device employs near-infrared imaging to visualize superficial vein patterns, while Doppler ultrasound provides the necessary depth and flow-rate data to distinguish between venous and arterial structures. This is a critical safety constraint: if the system fails to confirm a suitable vein, the logic gate prevents the needle from deploying.
It handles skin disinfection, needle insertion, and the precise mechanical movement required for tube switching. If a patient experiences involuntary movement, the system’s onboard accelerometers and proximity sensors trigger an immediate interrupt, detaching the needle to prevent tissue damage.
Performance Benchmarks and Clinical Validation
The FDA granted the De Novo marketing authorization based on clinical trial data indicating that the Aletta achieves successful blood draw rates comparable to, or in some scenarios exceeding, those of human phlebotomists. The trial population included high-variability cohorts, specifically those self-reporting difficult venous access and participants with diverse skin tones, ensuring the ultrasound and infrared algorithms maintain high signal-to-noise ratios across different physiological profiles.
Unlike traditional manual procedures, the Aletta standardizes the tube-filling sequence via a mechanical carousel. The supervising phlebotomist acts as the final validation layer, confirming that all collection tubes are filled in the correct order and verifying sample volume. This hybrid approach—autonomous execution with human oversight—is designed to minimize the risk of pre-analytical errors, which are a primary cause of diagnostic delays in high-volume laboratories.
curl -X GET "https://api.aletta-health.local/v1/device/status" \
-H "Authorization: Bearer [API_TOKEN]" \
-H "Content-Type: application/json"
Regulatory Framework and Future Scaling
The FDA’s authorization of the Aletta is accompanied by “special controls,” a regulatory requirement that mandates specific labeling, performance testing, and clinical validation standards beyond standard general controls. According to Michelle Tarver, M.D., Ph.D., Director of the FDA’s Center for Devices and Radiological Health, this move is part of a broader pillar of innovation aimed at mitigating the impact of the national phlebotomist shortage.